AmCad BioMed Corporation (TPEX:4188)
Taiwan
· Delayed Price · Currency is TWD 12.00
0.00 (0.00%)
Apr 29, 2026, 1:22 PM CST
AmCad BioMed Revenue
In the year 2025, AmCad BioMed had annual revenue of 30.44M TWD, down -42.69%. AmCad BioMed had revenue of 5.07M in the quarter ending December 31, 2025, a decrease of -72.08%.
Revenue
30.44M
Revenue Growth
-42.69%
P/S Ratio
24.97
Revenue / Employee
895.21K
Employees
34
Market Cap
759.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.44M | -22.67M | -42.69% |
| Dec 31, 2024 | 53.11M | -12.15M | -18.62% |
| Dec 31, 2023 | 65.26M | 3.63M | 5.88% |
| Dec 31, 2022 | 61.63M | -24.16M | -28.16% |
| Dec 31, 2021 | 85.79M | 21.85M | 34.17% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Radiant Innovation | 387.58M |
| S&S Healthcare Holding | 204.21M |
| PlexBio | 127.10M |
| Wiltrom | 311.77M |
| Health & Life | 398.05M |
| AViTA | 936.39M |
| Rossmax International | 3.80B |
| Diamond Biotechnology | 698.11M |